A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
A closer look at how reading, conversation, and AI are being combined
Updated
February 7, 2026 2:18 PM
Assorted plush character toys piled inside a glass claw machine. PHOTO: ADOBE STOCK
In the past, “educational toys” usually meant flashcards, prerecorded stories or apps that asked children to tap a screen. ChooChoo takes a different approach. It is designed not to instruct children at them, but to talk with them.
ChooChoo is an AI-powered interactive reading companion built for children aged three to six. Instead of playing stories passively, it engages kids in conversation while reading. It asks questions, reacts to answers, introduces new words in context and adjusts the story flow based on how the child responds. The goal is not entertainment alone, but language development through dialogue.
That idea is rooted in research, not novelty. ChooChoo is inspired by dialogic reading methods from Yale’s early childhood language development work, which show that children learn language faster when stories become two-way conversations rather than one-way narration. Used consistently, this approach has been shown to improve vocabulary, comprehension and confidence within weeks.
The project was created by Dr. Diana Zhu, who holds a PhD from Yale and focused her work on how children acquire language. Her aim with ChooChoo was to turn academic insight into something practical and warm enough to live in a child’s room. The result is a device that listens, responds and adapts instead of simply playing content on command.
What makes this possible is not just AI, but where that AI runs.
Unlike many smart toys that rely heavily on the cloud, ChooChoo is built on RiseLink’s edge AI platform. That means much of the intelligence happens directly on the device itself rather than being sent back and forth to remote servers. This design choice has three major implications.
First, it reduces delay. Conversations feel natural because the toy can respond almost instantly. Second, it lowers power consumption, allowing the device to stay “always on” without draining the battery quickly. Third, it improves privacy. Sensitive interactions are processed locally instead of being continuously streamed online.
RiseLink’s hardware, including its ultra-low-power AI system-on-chip designs, is already used at large scale in consumer electronics. The company ships hundreds of millions of connected chips every year and works with global brands like LG, Samsung, Midea and Hisense. In ChooChoo’s case, that same industrial-grade reliability is being applied to a child’s learning environment.
The result is a toy that behaves less like a gadget and more like a conversational partner. It engages children in back-and-forth discussion during stories, introduces new vocabulary in natural context, pays attention to comprehension and emotional language and adjusts its pace and tone based on each child’s interests and progress. Parents can also view progress through an optional app that shows what words their child has learned and how the system is adjusting over time.
What matters here is not that ChooChoo is “smart,” but that it reflects a shift in how technology enters early education. Instead of replacing teachers or parents, tools like this are designed to support human interaction by modeling it. The emphasis is on listening, responding and encouraging curiosity rather than testing or drilling.
That same philosophy is starting to shape the future of companion robots more broadly. As edge AI improves and hardware becomes smaller and more energy efficient, we are likely to see more devices that live alongside people instead of in front of them. Not just toys, but helpers, tutors and assistants that operate quietly in the background, responding when needed and staying out of the way when not.
In that sense, ChooChoo is less about novelty and more about direction. It shows what happens when AI is designed not for spectacle, but for presence. Not for control, but for conversation.
If companion robots become part of daily life in the coming years, their success may depend less on how powerful they are and more on how well they understand when to speak, when to listen and how to grow with the people who use them.